ADMA · trading date Oct 13, 2026 · previous close $10.19 · source: Alpaca (IEX feed, not consolidated full-market data).
Key Financials
Revenue
$510.17M
Net income
$146.93M
Total assets
$624.24M
Total liabilities
$146.92M
Stockholders' equity
$477.32M
Cash & equivalents
$87.63M
Operating income
$191.44M
Operating cash flow
$50.40M
Capital expenditures
$22.58M
Fiscal year 2025, via 10-K filed 2026-02-25.
A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
37.5%
Net margin
28.8%
Free cash flow
$27.82M
Free cash flow margin
5.5%
Liabilities / assets
23.5%
Equity / assets
76.5%
CapEx / revenue
4.4%
Operating cash flow / net income
0.34×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Ramsey, NJ 07446
C/O ADMA BIOLOGICS, INC.
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:39 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.